NUVL
Nuvalent IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$8.07B
P/E Ratio
—
EPS
$-6.06
Beta
1.15
52W High
$113.02
52W Low
$70.25
50-Day MA
$102.15
200-Day MA
$96.62
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Nuvalent Inc
Nuvalent Inc. is an innovative clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer patients with genetically defined diseases. Leveraging its proprietary drug discovery platform, Nuvalent aims to provide cutting-edge treatment solutions that specifically target genetic mutations driving tumor growth, ultimately enhancing patient outcomes and minimizing adverse effects. With a strong pipeline of highly selective therapies, the company is well-positioned to capitalize on the expanding precision oncology market, demonstrating a steadfast commitment to revolutionizing cancer treatment and improving patient care across the oncology sector.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -41.20% |
| Return on Assets | -22.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $14.89 |
| Price-to-Book | 6.87 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -22.26 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $73.56M |
| Float | $49.00M |
| % Insiders | 2.76% |
| % Institutions | 113.24% |
Historical Volatility
HV 10-Day
26.53%
HV 20-Day
31.17%
HV 30-Day
30.19%
HV 60-Day
30.52%
HV Rank
6.7%
Volatility is currently contracting
Analyst Ratings
Consensus ($144.52 target)
4
Strong Buy15
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026